Clinical Trial

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 5, 2024 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
A phase III multi-center randomized, double-blind and positive-controlled clinical trial for evaluating the efficacy and safety of BCG for Therapeutic Use（BCG） in the prevention of postoperative recurrence of medium/high-risk non-muscle invasive bladder cancer (NMIBC).
Trial Details
NCT Number NCT06241755
Lead Sponsor Chengdu CoenBiotech Co., Ltd
Collaborators: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions Non-Muscle Invasive Bladder Cancer
Enrollment 412 participants
Start Date 2023-12-28
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-09-03 (estimated)
Updated on ClinicalTrials.gov 2024-02-05